{"database": "lobbying", "table": "lobbying_activities", "rows": [[1145561, "c72e8950-7683-4433-82f7-e49d60cf335e", "Q3", "DALRYMPLE & ASSOCIATES, LLC", 5073, "BRIGHTON BIOTECH, INC.", 2011, "third_quarter", "MED", "Biodefense small molecule medical countermeasure against CBRN threats and orphan drug research and development funding, legislation, appropriations and oversight.", "Army, Dept of (Other),Ballistic Missile Defense Organization,Centers For Disease Control & Prevention (CDC),Defense, Dept of (DOD),Defense Threat Reduction Agency (DTRA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office", 16000, null, 0, 0, "2011-10-07T14:54:35.007000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1145561"], "units": {}, "query_ms": 14.211336034350097, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}